ArticleJGH open : an open access journal of gastroenterology and hepatology2021
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.Journal of clinical medicine · 2024Article
- Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.Scientific reports · 2024Article
- Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.Journal of clinical medicine · 2024Review
- Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.Advances in therapy · 2023Article
- Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.Therapeutic advances in gastroenterology · 2023Article
- Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.Therapeutic advances in chronic disease · 2023Article
- Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.Biomedicines · 2022Article
- Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies.Journal of clinical medicine · 2022Review
- A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.Alimentary pharmacology & therapeutics · 2022Article
- A review of the therapeutic management of Crohn's disease.Therapeutic advances in gastroenterology · 2022Review
- Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.Therapeutic advances in gastroenterology · 2022Article
- Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimUstekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real-life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients.
methodsData of patients with CD who started using ustekinumab were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. Primary end-points were steroid-free clinical remission at 8, 24, and 52 weeks of therapy and reduction of C-reactive protein. Secondary end-points were treatment response, treatment persistence at 12 months, and safety.
resultsA total of 131 patients (males 56%; mean age 46 years
conclusionsData from our real-life cohort of treatment-refractory CD patients suggest the satisfactory effectiveness and safety profile of ustekinumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.